Debra Patt and Eay Page: Support bipartisan fixes to the 340B Drug Discount Program

coapharm2018-05-29T13:27:29+00:00May 29, 2018|

Proposed Drug Price Changes to Increase Patient Out-of-Pocket Costs

coapharm2018-05-29T13:26:09+00:00May 29, 2018|

‘Paying Twice’: A Push for Affordable Prices for Taxpayer-Funded Drugs

coapharm2018-05-29T13:25:11+00:00May 29, 2018|

How banks and law firms make millions from hospital debt

coapharm2018-05-23T13:31:09+00:00May 23, 2018|

For cancer patients, Trump’s drug pricing proposal falls short

coapharm2018-05-23T13:30:08+00:00May 23, 2018|

Who Best Managed the Drug Spending Slowdown in 2017: CVS Health, Express Scripts, MedImpact, or Prime Therapeutics?

coapharm2018-05-23T13:29:17+00:00May 23, 2018|

Early 340B hospitals gave more uncompensated care than later participants

coapharm2018-05-23T13:27:58+00:00May 23, 2018|

Avalere Analysis Highlights Complexities of Transitioning Medicare Part B Drugs into Part D

coapharm2018-05-22T13:04:52+00:00May 22, 2018|

How pharmacy-benefit managers affect you — and your wallet

coapharm2018-05-22T13:03:42+00:00May 22, 2018|

The Art Of The Drug Deal

coapharm2018-05-22T13:02:33+00:00May 22, 2018|